Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BLISSGVS.NSthis companyBliss GVS Pharma Limited	₹654.75	18.76×	2.03×	2.61×	10.25×	-99.6%	54.2%	14.1%	13.9%	10.8%	7.3%	3.4%	0.02×	-0.06×	10.87×	4.02×	0.4%	6	17.76	3	B
AKUMS.NSAkums Drugs & Pharmaceuticals Ltd.	₹765.85	27.96×	2.15×	1.64×	10.95×	-35.7%	21.5%	8.4%	5.9%	7.7%	5.6%	13.7%	0.05×	-0.36×	3.91×	3.25×	0.0%	—	—	2	C
ERIS.NSEris Lifesciences Limited	₹1,255.50	28.62×	4.54×	5.67×	18.04×	108.8%	47.9%	26.9%	19.8%	15.9%	12.6%	0.3%	0.6×	2.07×	4.36×	0.74×	0.0%	5	3.5	3	B+
INDOCO.NSIndoco Remedies Limited	₹219.34	-15.33×	1.55×	0.79×	17.79×	-262.3%	40.7%	0.8%	-5.3%	-10.5%	0.7%	-7.9%	1.16×	7.5×	0.13×	1.13×	0.1%	6	1.81	2	C
INNOVACAP.NSInnova Captab Limited	₹1,068.90	28.01×	3.62×	2.46×	20.43×	-208.4%	32.6%	10.3%	8.8%	12.9%	8.4%	0.9%	0.32×	1.62×	9.74×	1.87×	0.3%	4	—	2	C
JAGSNPHARM.NSJagsonpal Pharmaceuticals Limited	₹217.42	29.01×	4.53×	4.35×	18.35×	83.7%	63.7%	16.9%	15.0%	15.6%	12.6%	3.7%	0.03×	-0.03×	47.31×	5.06×	1.3%	5	13.66	4	A
Peer median	—	28.01×	3.62×	2.46×	18.04×	-35.7%	40.7%	10.3%	8.8%	12.9%	8.4%	0.9%	0.32×	1.62×	4.36×	1.87×	0.1%	5	3.5	2	—